ABSTRACT
An analysis of results of complex clinico-immunological studies in 110 patients with liver cirrhosis complicated by portal hypertension has been made. A scheme of immunocorrective therapy with T-activin in patients with liver cirrhosis complicated by portal hypertension is substantiated and developed for performing roentgen endovascular interventions.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Embolization, Therapeutic , Hypertension, Portal/therapy , Liver Cirrhosis/therapy , Peptides/therapeutic use , Thymus Extracts/therapeutic use , Adult , Combined Modality Therapy , Female , Humans , Hypertension, Portal/etiology , Hypertension, Portal/immunology , Immunity, Cellular , Liver Cirrhosis/complications , Liver Cirrhosis/immunology , Male , Middle Aged , Radiography, Interventional , Splenectomy , Time FactorsABSTRACT
The article deals with the results of treatment of 27 patients with profuse esophageal hemorrhage in portal hypertension. Sixteen patients were treated by roentgen-guided endovascular surgery, namely, transhepatic transportal embolization of varicose veins of the esophagus and stomach. In view of the peculiarities of blood drainage and for the prevention of recurrent bleeding, seven patients were subjected to additional manipulations: embolization of the splenic artery (4) and the left gastric artery (3). Despite reliable arrest of bleeding, 3 patients died in the first 2-3 days from progressive hepatorenal failure. Only one patient had recurrent bleeding in the late-term period. The authors believe transhepatic transportal embolization of the gastroesophageal veins at the peak of hemorrhage to be a hardly injurious and effective method for its arrest.